BRPI0822068A2 - Derivado de 17-(-1'-propenil)-17-3'-oxidoestra-4-en-3-ona, seu uso e o medicamento contendo o derivado - Google Patents

Derivado de 17-(-1'-propenil)-17-3'-oxidoestra-4-en-3-ona, seu uso e o medicamento contendo o derivado

Info

Publication number
BRPI0822068A2
BRPI0822068A2 BRPI0822068-9A BRPI0822068A BRPI0822068A2 BR PI0822068 A2 BRPI0822068 A2 BR PI0822068A2 BR PI0822068 A BRPI0822068 A BR PI0822068A BR PI0822068 A2 BRPI0822068 A2 BR PI0822068A2
Authority
BR
Brazil
Prior art keywords
derivative
oxidoestra
propenyl
medicine containing
medicine
Prior art date
Application number
BRPI0822068-9A
Other languages
English (en)
Inventor
Ulrich Klar
Joachim Kuhnke
Rolf Bohlmann
Jan Hübner
Sven Ring
Thomas Frenzel
Frederik Menges
Steffen Borden
Hans Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Akltiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0822068(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Akltiengesellschaft filed Critical Bayer Schering Pharma Akltiengesellschaft
Publication of BRPI0822068A2 publication Critical patent/BRPI0822068A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/001—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class spiro-linked
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BRPI0822068-9A 2007-12-29 2008-12-23 Derivado de 17-(-1'-propenil)-17-3'-oxidoestra-4-en-3-ona, seu uso e o medicamento contendo o derivado BRPI0822068A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007063500A DE102007063500A1 (de) 2007-12-29 2007-12-29 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
PCT/EP2008/011161 WO2009083268A2 (de) 2007-12-29 2008-12-23 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-derivat, dessen verwendung und das derivat enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
BRPI0822068A2 true BRPI0822068A2 (pt) 2015-06-23

Family

ID=40679349

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822068-9A BRPI0822068A2 (pt) 2007-12-29 2008-12-23 Derivado de 17-(-1'-propenil)-17-3'-oxidoestra-4-en-3-ona, seu uso e o medicamento contendo o derivado

Country Status (23)

Country Link
US (1) US9034856B2 (pt)
EP (1) EP2238147B1 (pt)
JP (1) JP5600069B2 (pt)
KR (1) KR20100102190A (pt)
CN (1) CN101918426A (pt)
AR (1) AR069964A1 (pt)
AU (1) AU2008342912A1 (pt)
BR (1) BRPI0822068A2 (pt)
CA (1) CA2710934C (pt)
CL (1) CL2008003885A1 (pt)
CR (1) CR11541A (pt)
DE (1) DE102007063500A1 (pt)
DO (1) DOP2010000201A (pt)
EC (1) ECSP10010316A (pt)
ES (1) ES2397985T3 (pt)
IL (1) IL206381A0 (pt)
MX (1) MX2010007269A (pt)
PA (1) PA8807901A1 (pt)
PE (1) PE20091185A1 (pt)
TW (1) TW200940562A (pt)
UY (1) UY31582A1 (pt)
WO (1) WO2009083268A2 (pt)
ZA (1) ZA201005397B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
CH559220A5 (pt) * 1970-03-06 1975-02-28 Ciba Geigy Ag
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3702383A1 (de) * 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4232521A1 (de) * 1992-09-22 1994-03-24 Schering Ag Gestagen wirksame 4,5;11,12-Estradiene, Verfahren zu ihrer Herstellung, diese Estradiene enthaltende Arzneimittel sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
EP2238147B1 (de) 2012-10-24
ZA201005397B (en) 2012-01-25
CR11541A (es) 2010-08-05
EP2238147A2 (de) 2010-10-13
AU2008342912A1 (en) 2009-07-09
KR20100102190A (ko) 2010-09-20
DOP2010000201A (es) 2010-07-15
CL2008003885A1 (es) 2010-05-07
WO2009083268A2 (de) 2009-07-09
TW200940562A (en) 2009-10-01
UY31582A1 (es) 2009-08-03
US9034856B2 (en) 2015-05-19
MX2010007269A (es) 2010-10-15
JP2011507925A (ja) 2011-03-10
JP5600069B2 (ja) 2014-10-01
US20100317632A1 (en) 2010-12-16
AR069964A1 (es) 2010-03-03
CA2710934A1 (en) 2009-07-09
WO2009083268A3 (de) 2009-09-24
DE102007063500A1 (de) 2009-07-02
CN101918426A (zh) 2010-12-15
ES2397985T3 (es) 2013-03-12
ECSP10010316A (es) 2010-08-31
IL206381A0 (en) 2010-12-30
CA2710934C (en) 2015-07-21
PE20091185A1 (es) 2009-09-06
PA8807901A1 (es) 2009-07-23

Similar Documents

Publication Publication Date Title
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
BRPI0813455A2 (pt) Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
IL225206A (en) A derivative of multinuclear carbamoylpyridone, its pharmaceutical composition and its use
BRPI0810523A2 (pt) Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
EP1933936A4 (en) IMPREGNATED ENVELOPE OF MEDICAMENT
BRPI0923725A2 (pt) "compostos absorventes de uv trifuncionais e uso dos mesmos".
NO20082249L (no) Fusert heterocyklisk derivat, medisinsk sammensetning inneholdende samme samt medisinsk bruk derav
BRPI0813244A2 (pt) Compostos e seus usos 708
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0811865A2 (pt) Derivados heterocíclicos pirrolo-nitrogenados, a preparação e o uso farmacêutico dos mesmos
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0718192A2 (pt) Corantes dispersos, sua preparação e seu uso.
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
BRPI0818690A2 (pt) Derivados de quinazolinediona, sua preparação e seus usos terapêuticos.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0808798A2 (pt) Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas
BRPI0812766A2 (pt) 4-cloro-4-alcóxi-1,1,1-triflúor-2-butanonas, preparação das mesmas e uso das mesmas no preparo de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
PL1921210T3 (pl) Element zabezpieczający przed lawiną i tym podobnymi
BRPI0813937A2 (pt) Derivado de 17beta-ciano-19-nor-andros-4-eno, seu uso e medicamentos contendo o derivado

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.